TrialAnnals of surgical oncology2012

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Dian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.